Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCR | P30988 | 4/20 | 0.39 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGAV | P06756 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | GLP1R | P43220 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 4/20 | 0.36 |
| ▸ | FNTB | P49356 | 4/20 | 0.36 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4200040 | 1.00 | CALCR (0.39) | CALCRIL23RITGB3ITGAVHCRTR1 | |
| SCHEMBL29682077 | 0.96 | CALCR (0.40) | CALCRIL23RHCRTR1HCRTR2GLP1R | |
| SCHEMBL4216003 | 0.96 | CALCR (0.39) | CALCRIL23RHCRTR1HCRTR2FNTA | |
| SCHEMBL31320779 | 0.94 | CALCR (0.40) | CALCRIL23RITGB3ITGAVHCRTR1 | |
| SCHEMBL29622914 | 0.93 | SLC15A2 (0.38) | ITGB3ITGAVCRHR1CRHR2SLC15A2 | |
| SCHEMBL29833166 | 0.91 | CALCR (0.38) | CALCRIL23RHCRTR1HCRTR2SLC15A2 | |
| SCHEMBL31514341 | 0.89 | BACE1 (0.38) | CALCRGLP1RCRHR1CRHR2SLC15A2 | |
| SCHEMBL31717951 | 0.89 | C5AR1 (0.39) | CALCRIL23RFNTAFNTBSLC15A2 | |
| SCHEMBL30600995 | 0.89 | SLC15A2 (0.39) | SLC15A2 | |
| SCHEMBL29530841 | 0.89 | SLC15A2 (0.39) | ITGB3ITGAVSLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200032272-A1 | HYBRID IMMUNOGLOBULINS WITH MOVING PARTS | BIOMOLECULAR HOLDINGS LLC | 2020-01-30 | — | — | US | claimed |
| CN-101965363-A | Hybrid immunoglobulins with mobile moieties | CAPON DANIEL J | 2011-02-02 | — | — | CN | claimed |
| WO-2008140477-A9 | HYBRID IMMUNOGLOBULINS WITH MOVING PARTS | CAPON DANIEL J (US) | 2009-10-15 | — | — | WO | claimed |
| EP-2078040-A2 | HYBRID IMMUNOGLOBULINS WITH MOVING PARTS | Capon, Daniel J. (US) | 2009-07-15 | — | — | EP | claimed |
| WO-2008140477-A2 | HYBRID IMMUNOGLOBULINS WITH MOVING PARTS | CAPON DANIEL J (US) | 2008-11-20 | — | — | WO | claimed |
| EP-3284825-B1 | METHODS OF PRODUCING HYBRID POLYPEPTIDES WITH MOVING PARTS | BIOMOLECULAR HOLDINGS LLC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-20200032272-A1 | HYBRID IMMUNOGLOBULINS WITH MOVING PARTS | BIOMOLECULAR HOLDINGS LLC | 2020-01-30 | — | — | US | disclosed |
| US-10428332-B2 | Hybrid immunoglobulins with moving parts | BIOMOLECULAR HOLDINGS LLC | 2019-10-01 | — | — | US | disclosed |
| EP-3284825-A1 | METHODS OF PRODUCING HYBRID POLYPEPTIDES WITH MOVING PARTS | Capon, Daniel J. (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-2078040-B1 | Methods of producing hybrid polypeptides with moving parts | CAPON DANIEL J (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20160376601-A1 | Hybrid immunoglobulins with moving parts | BIOMOLECULAR HOLDINGS LLC | 2016-12-29 | — | — | US | disclosed |
| CN-101965363-A | Hybrid immunoglobulins with mobile moieties | CAPON DANIEL J | 2011-02-02 | — | — | CN | disclosed |
| WO-2008140477-A9 | HYBRID IMMUNOGLOBULINS WITH MOVING PARTS | CAPON DANIEL J (US) | 2009-10-15 | — | — | WO | disclosed |
| EP-2078040-A2 | HYBRID IMMUNOGLOBULINS WITH MOVING PARTS | Capon, Daniel J. (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008140477-A2 | HYBRID IMMUNOGLOBULINS WITH MOVING PARTS | CAPON DANIEL J (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080254512-A1 | Hybrid immunoglobulins with moving parts | BIOMOLECULAR HOLDINGS LLC | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428332-B2 | Hybrid immunoglobulins with moving parts | FCGRT, IGLV6-57, FCGR3B | CALCR 3054/4885IL23R 41/4885ITGB3 103/4885 |
| US-20080254512-A1 | Hybrid immunoglobulins with moving parts | FCGRT, IGLV6-57, FCGR3B | CALCR 3054/4885IL23R 41/4885ITGB3 103/4885 |
| US-20200032272-A1 | HYBRID IMMUNOGLOBULINS WITH MOVING PARTS | IGLV6-57, FCGRT, FCGR3B | CALCR 3193/4885IL23R 46/4885ITGB3 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.